StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

StockNews.com lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning.

Several other research analysts have also recently commented on COLL. Needham & Company LLC reissued a hold rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Jefferies Financial Group raised Collegium Pharmaceutical from a hold rating to a buy rating and boosted their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. HC Wainwright raised Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 target price for the company in a research note on Tuesday, July 30th. Piper Sandler reissued a neutral rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a buy rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of Moderate Buy and a consensus target price of $42.00.

Collegium Pharmaceutical Trading Up 0.6 %

Shares of NASDAQ COLL opened at $36.26 on Tuesday. Collegium Pharmaceutical has a twelve month low of $20.95 and a twelve month high of $40.95. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The stock has a fifty day simple moving average of $33.82 and a 200-day simple moving average of $35.00. The stock has a market capitalization of $1.19 billion, a PE ratio of 15.11 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the previous year, the firm posted $1.13 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. On average, equities analysts forecast that Collegium Pharmaceutical will post 5.73 earnings per share for the current year.

Insider Transactions at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. Pacer Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after purchasing an additional 821,541 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Collegium Pharmaceutical by 411.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after purchasing an additional 291,286 shares during the last quarter. LSV Asset Management raised its stake in Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after acquiring an additional 248,751 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after acquiring an additional 188,347 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.